Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual combination of paxalisib and immunotherapy could advance the treatment of ...

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase ...

The model, which is predominantly based on genetic gain- or loss-of-function studies, implies that RAS is locked into an active state in cancer and ... effector pathway in pancreatic ductal ...

A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic ...